• Allē Members Can Celebrate with Double Points and Enter for a Chance to Win $5,000

IRVINE, Calif., June 6, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), the makers of BOTOX® Cosmetic (onabotulinumtoxinA), is celebrating 25 years of SkinMedica®. To mark this milestone anniversary, Allē Members who purchase SkinMedica® products at a participating Allē Health Care Provider or SkinMedica.com from June 1 to June 25, 2024 can earn double points* and enter for a chance to win $5,000.**

"For 25 years, SkinMedica® has been delivering scientifically based skincare to patients and helping them to unlock the potential to have beautiful skin," said Jasson Gilmore, Senior Vice President of U.S. Aesthetics at Allergan Aesthetics. "We want to thank everyone who is a part of the SkinMedica® family from its founders to our scientists, our employees, our customers and of course, everyone who uses SkinMedica®!"

Since 1999, SkinMedica® has developed high-quality, science-backed formulas that deliver visible results. The initial product launch of Dermal Repair Cream was soon followed by the groundbreaking TNS Recovery Complex®, TNS Essential Serum®, and TNS® Advanced+ Serum, establishing the brand as a fixture in the industry. Throughout its evolution, SkinMedica® would continue to introduce new, innovative formulations to SkinMedica® loyalists and newcomers for years to come.

"Twenty-five years ago, we founded SkinMedica® with a vision—to create a skincare line that's both scientific and luxurious, yet easy to use," reflected Dr. Kimberly Butterwick, a double board-certified dermatologist and SkinMedica® co-founder. "Our breakthrough TNS® product, developed through a unique process that harnessed growth factors, transformed SkinMedica® from a startup into a brand known for innovation and excellence."

"Beautiful skin is timeless," Dr. Butterwick continues. "For 25 years, SkinMedica® has helped people feel more confident in their own skin, and I continue to count on them to provide science-based solutions to address my patients' key skincare concerns. As we celebrate this anniversary, I look forward to seeing how SkinMedica® continues to innovate and provide exceptional skincare in the next 25 years."

Follow @SkinMedica on Instagram to stay updated on exciting 25th anniversary promotions this month. Use the hashtag #25YearsOfSkinMedica to join in on the celebrations and share your SkinMedica® skincare journey. To learn more about the SkinMedica® range of exceptional products, visit SkinMedica.com.

*Terms and conditions apply to the double points offer.

**NO PURCHASE NECESSARY for sweepstakes. Open to Allē Members in 50 U.S./D.C.; age 18+ (19+ in AL & NE; 21+ in MS). Starts at 12:00:01 AM PT on 6/1/24; ends at 11:59:59 PM PT on 6/25/24. Allē Members must be logged into their Allē account if purchasing from SkinMedica.com or a Brilliant Connections™ online retailer for such purchases to be eligible for this promotion. See full Official Rules for all details and how to enter without purchase at https://alle.com/sweeps/skinmedica-25th-celebration. Sponsor: Allergan, Inc.

About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

BOTOX® COSMETIC IMPORTANT SAFETY INFORMATION AND APPROVED USES

Approved Uses
BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe forehead lines, crow's feet lines, and frown lines between the eyebrows in adults.

IMPORTANT SAFETY INFORMATION
BOTOX® Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic:

  • Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months.
  • Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing.

BOTOX® Cosmetic dosing units are not the same as, or comparable to, any other botulinum toxin product.

There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines, crow's feet lines, and/or forehead lines.

BOTOX® Cosmetic may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of taking BOTOX® Cosmetic. If this happens, do not drive a car, operate machinery, or do other dangerous activities.

Serious and/or immediate allergic reactions have been reported. They include: itching, rash, red itchy welts, wheezing, asthma symptoms, or dizziness or feeling faint. Get medical help right away if you are wheezing or have asthma symptoms, or if you become dizzy or faint.

Do not receive BOTOX® Cosmetic if you: are allergic to any of the ingredients in BOTOX® Cosmetic (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc® (rimabotulinumtoxinB), Dysport® (abobotulinumtoxinA), or Xeomin® (incobotulinumtoxinA); have a skin infection at the planned injection site.

Tell your doctor about all your muscle or nerve conditions, such as ALS or Lou Gehrig's disease, myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects including difficulty swallowing and difficulty breathing from typical doses of BOTOX® Cosmetic.

Tell your doctor about all your medical conditions, including: plans to have surgery; had surgery on your face; have trouble raising your eyebrows; drooping eyelids; any other abnormal facial change; are pregnant or plan to become pregnant (it is not known if BOTOX® Cosmetic can harm your unborn baby); are breast-feeding or plan to (it is not known if BOTOX® Cosmetic passes into breast milk).

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using BOTOX® Cosmetic with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received BOTOX® Cosmetic in the past. 

Tell your doctor if you have received any other botulinum toxin product in the last 4 months; have received injections of botulinum toxin such as Myobloc®, Dysport®, or Xeomin® in the past (tell your doctor exactly which product you received); have recently received an antibiotic by injection; take muscle relaxants; take an allergy or cold medicine; take a sleep medicine; take aspirin-like products or blood thinners.

Other side effects of BOTOX® Cosmetic include: dry mouth; discomfort or pain at the injection site; tiredness; headache; neck pain; and eye problems: double vision, blurred vision, decreased eyesight, drooping eyelids and eyebrows, swelling of your eyelids and dry eyes.

For more information refer to the Medication Guide or talk with your doctor. 

To report a side effect, please call Allergan at 1-800-678-1605.

Please see BOTOX® Cosmetic full Product Information including Boxed Warning and Medication Guide.

SkinMedica® Important Information 

Most SkinMedica® products are intended to meet the FDA's definition of a cosmetic product, an article applied to the human body to cleanse, beautify, promote attractiveness, and alter appearances. These SkinMedica® products are not intended to be drug products that diagnose, treat, cure, or prevent any disease or condition. These products have not been approved by the FDA and the statements have not been evaluated by the FDA. 

For more information, please talk to your provider or visit SkinMedica.com. To report an adverse reaction, please call Allergan at 1-800-433-8871. 

Allergan Aesthetics (PRNewsfoto/AbbVie)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/skinmedica-celebrates-25-years-of-empowering-radiant-skin-302165354.html

SOURCE AbbVie

Copyright 2024 PR Newswire

AbbVie (NYSE:ABBV)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024 Click aqui para mais gráficos AbbVie.
AbbVie (NYSE:ABBV)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024 Click aqui para mais gráficos AbbVie.